-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
10x Genomics today announced the barcode-based antigen profiling (BEAM) analysis product, a new solution for antibody discovery and T cell receptor (TCR) discovery
.
BEAM's antigen screening method is based on 10x Genomics' Chromium single-cell immunoassay product
.
According to reports, the entire process is fast and reliable, capable of binding single-cell gene expression to provide hundreds of antigen-receptor
pairs.
The screening process is not only quick and easy, but also proven
.
In addition, a comprehensive exploration of each cell is expected to greatly accelerate and improve therapeutic discovery
.
The task of matching antigens of interest to specific B cell or T cell receptors remains difficult and
costly.
Traditional methods are long-time, inefficient, and lack full-length paired V(D)J receptor sequences
.
BEAM addresses these challenges by providing ready-to-use kits that enable unique labeling and multiplexing
of antigens of interest.
The BEAM operation concept has been fully optimized and can be completed
in just one week.
It is also paired with easy-to-use software that identifies and matches
putative antigens and their homologous, full-length paired V(D)J receptors.
This is a comprehensive solution that explores the binding specificity of thousands of individual antigen-specific B cells and T cells, bringing a potential immune repertoire
against pathogens and diseases.
Antigen-specific BCR and TCR discovery processes
Bryan Briney, assistant professor at the Scripps Institute, said: "BEAM technology will greatly improve our understanding of infectious disease biology and accelerate the discovery of rare monoclonal antibodies
that have the specificity needed for treatment.
The BEAM workflow generates rich and powerful data that helps us understand immune tolerance to variants and will play a key role
in the design and development of durable vaccines.
”
Ben Hindson, co-founder and chief scientific officer of 10x Genomics, said: "Almost every disease is involved in some way the immune system – whether it is infectious disease, autoimmunity, cancer or inflammation – so a basic understanding of the immune response is essential to fully understand these diseases
.
”
"The advent of BEAM allows researchers to gain insight into the fundamental mechanisms of the immune system at high throughput and resolution, which can help translate the power of the natural immune response into the next wave of powerful, life-saving therapies," said Hindson
.
BEAM is the sixth major product
launched by 10x Genomics this year.
BEAM is available for pre-order today and is expected to ship from
December 2022.
